Lisa Dreyer - Page 18 - Pappas Capital

IlluminOss Medical Announces the Enrollment of First Patient in EU Humerus Fracture Repair Trial

Light Fix Trial at Vienna General Hospital Will Apply IlluminOss’ Minimally Invasive, Patient-Specific Bone Stabilization Technology

East Providence, RI/Vienna, Austria (March 3, 2015) – IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that the first patient has been enrolled in its EU Light Fix trial for the treatment of impending and pathologic fractures in the humerus due to metastatic carcinoma. The trial will be led by Prof. Reinhard Windhager, MD of the University Clinic of Vienna Orthopaedic Department. Prof. Windhager is a worldleading orthopedic oncologist who heads the Department of Orthopaedic Surgery at Vienna General Hospital (AKH). The EU Light Fix trial will enroll up to 45 patients at approximately 10 centers in Austria, Germany and the Netherlands.

IlluminOss Medical - 03/03/2015

Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem(R) Cell Therapy for Ischemic Stroke in Japan

Regenerative Medicine Partnership Focused on Development of Novel Stem Cell Therapy
CLEVELAND and TOKYO, March 2, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) and Chugai Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4519) have announced a partnership and license agreement to exclusively develop and commercialize MultiStem® cell therapy for ischemic stroke in Japan. Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan's aging population.

Athersys - 03/02/2015

Triangle Global Health Consortium Recognizes Chimerix with 2015 Corporate Impact Award

February 8, 2015 - The Triangle Global Health Consortium is pleased to recognize Chimerix, Inc. as the winner of our 2015 Corporate Impact Award, Chimerix, Inc. Chimerix is a biopharmaceutical company dedicated to preventing and treating life-threatening infections. Chimerix was chosen for their work in developing oral antivirals to prevent disease in individuals with weakened immune systems and to treat viral diseases where no treatment is available. The award will recognize the efforts of Chimerix over the last decade to advance the clinical program of their lead candidate, brincidofovir. Originally developed to treat smallpox, brincidofovir is also being studied to prevent or treat common viruses -- such as cytomegalovirus (CMV) and adenovirus -- that can be deadly in people with weakened immune systems, especially following a stem cell (bone marrow) or organ transplant.

Chimerix - 02/08/2015

Envisia Therapeutics Initiates Phase 2a Clinical Trial for ENV515 in Patients with Glaucoma

RESEARCH TRIANGLE PARK, NC – JANUARY 27, 2015 – Envisia Therapeutics today announced that it has initiated a phase 2a clinical trial to investigate the safety and tolerability of its lead product, ENV515, in patients with glaucoma. ENV515is a proprietary, fully biodegradable PRINT® (Particle Replication In Non-Wetting Templates) particleformulation of a prostaglandin analog, travoprost, with the potential forsustained intraocular pressure (IOP) reduction over as many as six months. ENV515 offersthe potential to significantly address the poor compliance that exists among glaucoma patients today to limit disease progression and vision loss.

Envisia Therapeutics - 01/27/2015

Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition

Innovate UK Grant Awarded for MultiStem(R) Therapy Clinical Trial in United Kingdom
LONDON and CLEVELAND, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Athersys Limited (an affiliate of Athersys, Inc.) (Nasdaq:ATHX) and the Cell Therapy Catapult, a not-for-profit centre, which is focused on the development of the United Kingdom cell therapy industry to increase the nation's health and wealth, are pleased to announce that Athersys Limited has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, which will support a Phase 2a clinical study evaluating the administration of MultiStem® cell therapy to acute respiratory distress syndrome (ARDS) patients.

Athersys - 01/22/2015

CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C Preferred Stock Offering

Durham, NC, January 13, 2015/PRNewswire/ -- CoLucid Pharmaceuticals, Inc., today announced that it has completed a $37.1 million Series C preferred stock offering. The financing was led by TVM Capital Life Science, based in Montreal and Munich,and included participation from new investors Novo Ventures and Auriga Partners. All of the Company’s existing investors also participated in the Series C, including Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures. Joining the board of directors will be Dr. Luc Marengere from TVM Capital Life Science and Dr. Martin Edwards from Novo Ventures.

CoLucid Pharmaceuticals - 01/13/2015

Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034

Opportunity to pursue multiple additional indications for brincidofovir

DURHAM, N.C., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering a method of synthesis and the commercial morphic form of brincidofovir. With the addition of this most recent patent, composition of matter coverage for brincidofovir in the U.S. is expected to extend to October 2034.

M. Michelle Berrey, M.D. M.P.H., President and CEO, said, "This important allowance significantly increases the patent protection of brincidofovir for our lead indications to prevent clinically significant cytomegalovirus infection in hematopoietic cell transplant recipients and for the treatment of adenovirus infection. Importantly, this will provide 20 years of patent coverage for Chimerix to pursue multiple additional indications in broad patient populations."

Chimerix - 01/12/2015

Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND

MONTREAL, Jan. 12, 2015 /PRNewswire/ - Milestone Pharmaceuticals, Inc. announced today that it received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 study of MSP-2017 for the treatment of acute episodes of Paroxysmal Supraventricular Tachycardia (PSVT). The trial is expected to begin patient enrollment in early 2015.

Milestone Pharmaceuticals - 01/12/2015

Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin

NOVATO, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced a license agreement with Inserm Transfert SA and Institut du Cerveau et de la Moelle Epiniere (ICM) for intellectual property related to the treatment of Huntington's disease with triheptanoin (UX007).

"Huntington's is a severe and lethal rare genetic disease," commented Emil D. Kakkis, Ph.D., M.D., Chief Executive Officer and President of Ultragenyx. "Energy deficiency is believed to play a role in the pathophysiology of Huntington's disease, and we are encouraged by data from a small pilot study suggesting improvement in brain energy metabolism after treatment with triheptanoin."

Ultragenyx Pharmaceutical - 01/07/2015

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300

SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in a Phase 2 clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat as a treatment for a select group of patients with bladder cancer. The trial will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300 genes.

Mirati Therapeutics - 01/07/2015